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ABSTRACT 
We used a discrete choice experiment to assess the acceptability and potential uptake 
of HIV pre-exposure prophylaxis (PrEP) among 713 HIV-negative members of fishing 
communities in Uganda. Participants were asked to choose between oral pill, injection, 
implant, condoms, vaginal ring (women), and men circumcision. Product attributes 
were HIV prevention effectiveness, sexually transmitted infection (STI) prevention, 
contraception, waiting time, and secrecy of use. Data were analysed using mixed 
multinomial logit and latent class models. HIV prevention effectiveness was viewed as 
the most important attribute. Both genders preferred oral PrEP. Women least preferred 
the vaginal ring and men the implant. Condom use was predicted to decrease by one 
third among men, and not to change amongst women. Oral PrEP and other new 
prevention technologies are acceptable among fishing communities and may have 
substantial demand. Future work should explore utility of multiple product technologies 
that combine contraception with HIV and other STI prevention.  
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Aceptabilidad y productores de la captación de antirretrovirales antes de la 
exposición. Profilaxis entre las comunidades de pescadores en Uganda: un 
corte transversal Encuesta de experimento de elección discreta.  
 
Utilizamos un experimento de elección discreta para evaluar la aceptabilidad y la 
aceptación potencial. Profilaxis de pre exposición al VIH entre 713 miembros de la 
comunidad de Pescadores que no tienen VIH. en Uganda. Se pidió a los participantes que 
eligieran entre la píldora oral y la inyección, Implantes, condones, anillos de vagina, y 
para circuncisión masculina. Atributos del product fueron efectividad en la prevención del 
VIH, prevención de infecciones de transmisión sexual, anticoncepción, tiempo de espera 
y secreto de uso. Los datos fueron analizados utilizando mixtos. Lógica y modelos de 
clase latente. La efectividad la prevención del VIH fue vista como el atributo más 
importante. Ambos géneros prefirieron la preparación oral/ píldora, las mujeres menos 
prefirió el anillo de vagina y los hombres el implante. Se predijo que el condón 
disminuiría en un tercio entre los hombres y no cambiaria entre las mujeres. La 
comunidad de pescadores acepta la preparación oral / píldora y otras tecnologías de 
prevención. y puede tener una demanda sustancial. El plan futuro debe explorar la 
utilidad de las tecnologías de múltiples productos que combinan la anticoncepción con el 
VIH y otras medidas de prevención de ITS. Palabras clave. personas más frescas, 
prevención del VIH, experimento de elección discreta, profilaxis previa a la exposición, 
Uganda. 
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INTRODUCTION 
Although new HIV infections in Eastern and Southern Africa declined by 30 between 
2010 and 2017, the region still accounts for 43% of new HIV infections globally(1). 
Fishing communities constitute about 10% of Uganda’s population and are one of the 
key populations at high risk of HIV-infection in Uganda (2-5). HIV prevalence among 
fishing communities is estimated to be five times the national average, with women 
disproportionately affected (2-4, 6-8). HIV incidence among fishing communities is 
estimated to be between 3.3 to 6.7 cases/100 person-years, compared to <1 cases/100 
person years at national level (3, 4, 9). This picture is mirrored in fishing communities 
elsewhere in sub-Saharan Africa (10).  
 
Fishing communities have increased susceptibility to HIV and other sexually transmitted 
infections (STI) due to complex and interacting factors including alcohol misuse and illicit 
drug use (2, 11-13), poor access to healthcare including HIV prevention and care 
services and transactional sex (4, 10, 14). High mobility in search for better fish yields 
and market for fish is a crucial livelihood strategy for fishing communities (15-17).  
However, high mobility comes with prolonged separation from family and high risk 
bahaviour both major risk factors for HIV acquisition and transmission. Similarly, cultural 
norms of hyper-asculinity, peer pressure, low perception of risk to HIV and the low 
socioeconomic and cultural status of women have been highlighted as drivers of the 
epidemic in fishing communities (3, 4, 8, 14, 18, 19).   
 
Novel prevention approaches are required to complement existing HIV prevention 
strategies to further reduce HIV incidence among fisher folk. A number of recently 
developed antiretroviral (ARV)-based HIV prevention modalities are considered in this 
study. Oral PrEP is recommended for use in Uganda and elsewhere (20-27), whilst the 
efficacy of intra-vaginal rings (28, 29), and microbicide gels (30) in reducing HIV risk 
has been shown in clinical trials. Long-acting injectable PrEP is undergoing phase 3 
clinical trials (31) to assess efficacy, effectiveness and safety of patients. Implants are 
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also a viable options for HIV prevention, whilst male circumcision has been shown to 
reduce HIV risk by up to 60%(32, 33). New HIV prevention products may increase 
population protection to HIV because they allow users to exercise choice of the most 
suitable HIV prevention method at the time they need it. Multipurpose HIV prevention 
technologies (MPTs) which provide users with more options for contraception and STI 
prevention prevent users from one or more of unintended pregnancy, HIV and STI are 
considered potentially attractive to reduce the health burden associated with HIV, STI 
and unintended pregnancies. Previous work has estimated MPTs to be potentially cost-
effective in high HIV incidence groups (37, 38). 
 
Guidelines for oral PrEP implementation for key populations have been published by the 
Centers for Disease Control and Prevention and the World Health Organization (34, 35). 
In addition, PrEP acceptability studies and demonstration projects have been widely 
conducted in other key populations such as female sex workers, men who have sex with 
men, serodiscordant couples, transgender, and intravenous drug users  (30, 36-41). 
However, these PrEP guidelines and demonstration studies do not address the special 
needs of fishing communities such as their high mobility and low perception of risk to 
HIV (42), which might have implications for PrEP service delivery and uptake. This is 
largely due to insufficient evidence at a micro-level, in local country and community 
contexts. Moreover fisher folk have extensive sexual networks which bridge into the 
general population (18, 43).  
 
Prior to roll-out of oral PrEP and other new HIV prevention products as part of the HIV 
combination prevention package for fishing communities, formative studies on 
acceptability are required. To obtain reliable estimates of preferences  and predictions of 
uptake of different forms of PrEP, we used a discrete choice experiment (DCE) 
methodology. DCEs ask respondents to make a number of choices between hypothetical 
HIV prevention options and allow us to evaluate the respondents’  preferences towards 
existing and possible future HIV prevention methods (44). Our study explored the effect 
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of product characteristics on preferences for five products (oral PrEP, vaginal ring, 
implant, injectable long-acting PrEP, male circumcision, male condom) to identify 
potential tradeoffs and predict uptake of products. The DCE was implemented within a 
cross-sectional survey in a stratified random sample of fishing communities around Lake 
Victoria.  
 
METHODS 
 
Study design and setting 
We conducted a cross sectional survey between December 2016 and March 2017 in four 
fishing communities around the shores of Lake Victoria (two rural, two urban) in the 
districts of Mpigi, Wakiso, and Kampala. The survey was nested in an HIV-combination 
prevention cluster randomized pilot study (HIVCOMB) conducted by the MRC/UVRI 
Uganda Research Unit on AIDS (45). Under the HIVCOMB study, in the year prior to DCE 
study, study communities received HIV prevention packages including male circumcision, 
male condoms, HIV testing, and behavior change communication. 
 
Discrete choice experiment  
Four months prior to the survey, we carried out formative research using qualitative 
methods to identify attributes and attribute levels. Attributes are the important 
characteristics of different choices. For example, one attribute could be HIV prevention 
effectiveness with attribute levels being 55%, 75%, or 95% (Table 1). 
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Table 1: DCE attributes and levels 
Product Oral PrEP, Vaginal ring, Implant, Injectable PrEP, Male 
Circumcision 
Opt out alternative: No product/condom  
HIV protection  55%, 75%, 95% 
STI protection Yes, No 
Contraception Yes, No 
Ability to use in 
secret ‡ 
Yes, No 
Waiting time * None, 1 hour, 2 hours 
* Waiting time was explained as including time to accessing product to using the product. This includes travel time and clinic waiting 
time.  
‡ Secrecy was defined as the ability for an individual to use a product without their sexual partners’ knowledge. 
 
 
This included a scoping review; 15 in-depth interviews with 8 men and 7 women; and 12 
focus group discussions (FGDs) (6 with men, 6 with women); 2 with HIV-infected 
persons, 10 with HIV negative persons; using semi-structured interview guides or open 
discussions. We conducted FGDs with HIV-infected persons to enrich the discussions on 
antiretroviral-based HIV prevention methods, in particular oral PrEP, given their 
experience of chronic medication. DCE tasks presented participants with choices between 
alternatives which were defined by the defined attributes.  To refine and validate the 
attributes and attribute levels, we conducted two workshops with a sub-sample (n=40) 
of the FGD and in-depth interview respondents. All respondents were aged 18 and over. 
To improve the accuracy, validity, credibility, and applicability of the final list of potential 
attributes and attribute levels, we used member checking and ranking exercises. 
The DCE had five attributes: HIV protection (effectiveness), STI protection, 
contraception, ability to use in secret, and waiting time. Waiting time included time to 
access and use the product including travel time and clinic waiting time. The product 
attributes and attribute levels of the final DCE were as shown in Table 1. Figure 1 gives 
an example of DCE tasks, as presented to respondents. The DCE was piloted among 10 
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people, with data analysed to generate a D-efficient statistical design for the final set of 
tasks in NGENE software (46). The final design incorporated ten choice tasks and 
participants were shown two new products and the option to opt-out. The opt-out 
alternative was a male condom for those who reported using a condom at last sex and 
no product for those who did not, thereby allowing more realistic uptake prediction (51). 
To inform respondents’ choice of potentially unfamiliar products, interviewers gave 
participants sample products with no active ingredient, showed respondents pictures of 
products on the computer tablet, and explained how each of the products was to be 
used. 
 
Figure 1: Example DCE task 
 
 
Survey 
 
Sample size and sampling 
We used a sampling frame from a previous study conducted in 2014-2015.A mapping and 
census exercise was done in each of the four communities. In each community, the census 
population was stratified into the six strata consisting of combinations of gender (male, 
female) and age (18-24 years, 24-34 years and 35 years or older), to ensure 
representation of gender and age groups. Participants’ HIV status was determined to 
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ensure approximately 200 HIV un-infected were included. The sampling fractions differed 
between strata to allow oversampling of HIV-uninfected respondents. The sampling 
fractions were chosen based on the HIV prevalence in previous literature (7). Respondents 
who were absent after three visits over a three-month period were replaced at random by 
respondents from the same fishing community, matched for age group, gender and HIV-
negative status. We replaced 87 missing respondents with respondents from the sample, 
matched for age, gender and HIV status, and realized a final sample size of 805. 
 
Respondent selection at household level 
Inclusion criteria were residence in the fishing community for over three months, age 18 
years and older, and consent to participate in the study. To prevent involuntary disclosure 
of HIV status, HIV positive respondents were included in the survey, however, data 
analyzed in this paper focused on HIV negative respondents only. During the study 
interviews, our team provided HIV testing to the wider community to enhance community 
engagement. 
 
Adults were excluded if they did not understand the common dialects (English or Luganda) 
used by the research team. All eligible respondents in a sampled household were selected 
to make the study more acceptable to the community. Sample weights inversely 
proportional to the sampling probability of a respondent were calculated for each of the 
six strata according to the target sampling probabilities. The sample weights were constant 
across the four study communities.  
 
Survey procedures 
At the community hubs (focal points and facilities that are easily accessible to community 
residents for health information and survey activities), survey staff conducted face-to-face 
screening of respondents for eligibility. Eligible respondents received pre-test counselling, 
HIV rapid testing and post-test counselling. We conducted face-to-face interviews in 
Luganda and collected data using android tablets running Open Data Kit software. The 
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research team was gender-balanced and experienced in working with fishing communities. 
In addition to the DCE tasks the survey included questions on socio-demographics, sexual 
behaviors in the last three months, contraception, substance use, sexual violence, STIs, 
and HIV prevention.  
 
Laboratory measures 
We conducted rapid HIV tests at the community-hub using a pre-defined approved 
standard operating procedure and national testing algorithm. Alere Determine HIV 1/2 
whole blood assay (Alere medical, Chiba, Japan), STAT-PAK rapid test HIV 1/2 (Chembio 
diagnostic systems NewYork, U.S.A) and Unigold (Trinity Biotech, Wicklow, Ireland) HIV 
confirmatory tests were conducted in an accredited laboratory using ELISA HIV Murex 
Diasori: Ref 9E25-02 UK and BIOKIT Bio Elisa HIV1/2 Ag/Ab, SPAI. All recruits enrolled 
into the survey accepted HIV testing. 
 
Data management and analysis 
 
DCE data 
We used a standard stated preference choice modelling approach, used extensively 
elsewhere in health, environmental, (47, 48) and transport economics (49). To model 
choice data from the DCE, we assume that each individual i(i=1,…,N) makes choices such 
that they maximize utility over the four alternatives presented (j=1,2,3,4). Their axiomatic 
utility function Uij is decomposed into an explainable systematic component Vij and a 
random component εij, and we specify an indirect utility function for the utility of 
respondent i from choice j in choice set c as the linear combination of attributes and an 
error term: 
𝑉𝑖𝑗𝑐 = 𝑋𝑖𝑗𝑐𝛽 + 𝜀𝑖𝑗𝑐 
(1) 
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With 𝑉𝑖𝑗𝑐 the utility derived from a choice, 𝑋𝑖𝑗𝑐
′ 𝛽 the component of utility that is captured 
by DCE attributes, and 𝜀𝑖𝑗𝑐 a stochastic (random) component of utility. We specify the 
vector 𝑋𝑖𝑗𝑐 as the set of product attributes: 
𝑋𝑖𝑗𝑐𝛽𝑗 = 𝛽0 +  𝛽1𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑗 + 𝛽2𝐻𝐼𝑉𝑗 + 𝛽3𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑒𝑝𝑡𝑖𝑜𝑛𝑗 + 𝛽4𝑆𝑇𝐼𝑗 + 𝛽5𝑆𝑒𝑐𝑟𝑒𝑡𝑗 + 𝛽6𝑇𝑖𝑚𝑒𝑗 
(2) 
 
 
 
Where 𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑗, 𝐻𝐼𝑉𝑗, 𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑒𝑝𝑡𝑖𝑜𝑛𝑗, 𝑆𝑇𝐼𝑗, 𝑆𝑒𝑐𝑟𝑒𝑡𝑗, and 𝑇𝑖𝑚𝑒𝑗 are the design attributes of the 
DCE, and 𝛽0 a constant. We first estimate equation (1) using a multinomial (or conditional) 
logit model (MNL) which estimates the probability of individual i choosing alternative j 
among the set of options c as a probabilistic function of design attributes: 
𝑃𝑖𝑗𝑐 =
exp (𝑋𝑖𝑗𝑐𝛽)
∑ exp (𝐽 𝑋𝑖𝑗𝑐𝛽)
 
(3) 
 
 
The MNL model requires two restrictive assumptions: independence of irrelevant 
alternatives (IIA) and homogenous preferences across individuals, the latter assuming 
that every individual has the same tastes as the sample average (47). We assume that 
individuals choose the service associated with the highest utility such that the probability 
that individual i chooses alternative j over k is given as: 
Pr 𝑗𝑖 = Pr(𝑈𝑗𝑖 > 𝑈𝑘𝑖) = Pr(𝑉𝑗𝑖 + 𝜀𝑗𝑖 >  𝑉𝑘𝑖 + 𝜀𝑘𝑖) = Pr(𝑉𝑗𝑖 − 𝑉𝑘𝑖 > 𝜀𝑗𝑖 − 𝜀𝑘𝑖) 
(4) 
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We take the standard approach to relaxing the IIA assumption and, as described by Hess 
et al. (49), estimate a mixed multinomial logit (MMNL) model where the parameter vector 
𝛽 is assumed to be randomly distributed rather than fixed, such that 𝛽~𝑓(𝛽, Ω): 
𝑃𝑛,𝑖 = ∫ 𝑃𝑛,𝑖
 
𝛽
(𝛽, 𝑥𝑛,𝑖)𝑓(𝛽, Ω)𝑑𝛽 
(3) 
 
 
Where Ω is a parameter vector of the distribution of the elements contained in 𝛽.  
A restriction of the MMNL model is that the analyst needs to specify which parameters are 
randomly distributed across agents, as well as the way they are distributed (i.e. according 
to a normal, lognormal, or uniform distribution). The requirement of these assumptions is 
generally seen as a small cost for the ability of MMNL specifications to allow for taste 
heterogeneity, where preferences are allowed to vary across individuals (47, 49).  
Finally, we explored preference heterogeneity through latent class modelling, which 
relaxes the IIA assumption across different groups of the sample. A latent class approach 
estimates separate parameter vectors for different classes of the sample with MNL models. 
The model relaxes the IIA assumption by assuming that preferences are homogenous 
within, but not across, classes. Thus the probability of respondent i choosing alternative j 
in choice set c conditional on class membership k is: 
𝑃𝑖𝑐(𝐽|𝛽𝑘) =  ∑ 𝜋𝑖𝑘
𝐾
𝑘=1
exp (𝑋𝑖𝑗𝑐𝛽𝑘)
∑ exp (𝐽 𝑋𝑖𝑗𝑐𝛽𝑘)
 
(7) 
 
 
The probability of respondent i belonging to class k is 𝜋𝑖𝑘. Class membership is 
unobservable, however, we can regress the probability of class membership on a set of 
observable characteristics such that: 
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𝜋𝑖𝑘 =
exp (𝑍𝑖
′𝛿𝑘)
∑ exp (𝑍𝑖
′𝛿𝑘)
𝐾
𝑘=1
 
(8) 
 
 
 Zi was the vector of individual characteristics, and 𝛿𝑘 was the vector of parameters for 
estimation. The number of classes was selected using Akaike Information Criteria (AIC) 
values and statistical inference of model results. 
Uptake predictions 
We use predicted probability analysis to simulate different scenarios of product uptake by 
substituting coefficients from the MNL model into equation 3, incorporating realistic 
product characteristics as follows. All new products were considered to be used in secret, 
whilst condoms were not, and efficacy assumptions were as follows: oral PrEP, injectable, 
implant – 61% (50), intravaginal ring - 56%, for women aged 21 years and over (51), 
condom - 87% (52), male circumcision – 67% (53). Predictions were made among condom 
users and non-users, and among circumcised and non-circumcised men before a weighted 
average of overall coverage was generated. Although there have been concerns that the 
reliance of DCE data on stated preferences means that their predictive validity may be 
low, published studies show that DCEs can predict with reasonable accuracy (88% 
specificity, 34% sensitivity) (59). 
 
Ethics statement  
Ethical approval was obtained from the Uganda Virus Research Institute Research Ethics 
Committee, Uganda National Council for Science and Technology, and the University of 
Washington. The survey was conducted anonymously and written informed consent was 
obtained from all participants.   
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RESULTS  
Sample characteristics 
We selected a sample of 1469 and reached 919 (63%) respondents. We enrolled 805 
respondents (55%). Ninety-three participants had left the study area, nine were 
deceased, 12 refused to participate. Descriptive statistics are shown in table 2.  
 
          Table 2: Descriptive statistics 
  
Men Women Total 
n=412   n=393 805 
[51%] [49%]   
Study sites       
Ggaba 89 (22) 95 (24) 184 
Gerenge 99 (24) 120(31) 219 
Ssenyondo 124 (30) 112 (28) 236 
Makungu 55 (13) 29 (7) 84 
Busimuzi 45 (11) 37 (9) 82 
  
      
Age group 
18-24 years 78 (19 ) 93 (24) 171 
25-29 years 83 (20) 93 (24) 176 
30-34 years 76 (19) 53 (14) 129 
35-39 years 61 (15) 61 (16) 122 
40-44 years 44(11) 39 (10) 83 
45-49 years 36 (9) 28 (7) 64 
≥ 50 years 34 (8) 26 (7) 60 
Median age (IQR; years) 32 (18-78) 30 (18-81) - 
Mean, SD 34 (11) 32 (11) - 
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Marital status 
Single 66 (16) 37 (10) 103 
In a steady sexual relationship lasting 
less than 3 months 
6 (2) 1 (0) 7 
In a steady sexual relationship lasting 
more than 3 months 
55 (14) 49 (13) 104 
In a casual sexual relationship lasting 
less than 3 months 
2 (0) 4 (1) 6 
In a casual sexual relationship lasting 
more than 3 months 
7 (1) 5 (1) 12 
Married, not living with husband/wife 30 (7) 20 (5) 50 
Not married, living as husband and wife 57 (14) 56 (15) 113 
Married, living with husband/wife 164 (40) 162 (42) 326 
Divorced / Widowed/ separated 15 (4) 40 (10) 55 
In a steady non-sexual relationship 
lasting less than 3 months 
1 (0.3) -   
In a steady non-sexual relationship 
lasting more than 3 months 
2 (0.5) 5 (1) 7 
Don’t know 2 (0) 5 (1) 7 
Other 2 5 7 
  
      
Education attainment (highest level) 
Pre-primary school 33  (9) 27 (8) 60 
Primary school 189 (52) 210 (63) 399 
Secondary school 125 (34) 86 (26) 211 
Tertiary (e.g. college/university) 17 (5) 6 (2) 23 
Vocational 3 (1) 2 (1) 5 
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Occupation 
Fishing related activities 147 (36) 49 (13) 196 
Restaurant/bar 1 (0) 50  (13) 51 
Itinerary trade  65 (16) 117 (30) 182 
Farmer 58 (14) 69 (18) 127 
Housewife - 52 (13) 52 
Student 7 (2) 6 (2) 13 
Elementary occupation 128 (31) 44 (11) 172 
Unemployed 6 (2) 6 (2) 12 
  
      
Age at first sex 
≤ 15 years 87 (21) 125 (33) 16 
16-18years 182 (45) 201 (52) 577 
≥19 years  138 (34) 58 (15) 196 
  
      
Male circumcision status 
Yes 241 (59) - 241 
No 166 (41) - 166 
 
 
Discrete choice modelling 
Table 3 shows the MNL model and displays model coefficients (preference weights) for 
each attribute level alongside its standard error. Although DCE tasks were presented to all 
respondents regardless of HIV status, we only present results from HIV negative persons 
because they are a priority group for uptake of the HIV prevention products considered in 
this study. The standard distribution columns present the standard distributions of the 
random parameters, and where significant indicate statistically significant heterogeneity 
in preferences across respondents. Almost all parameters are statistically significant from 
zero and consistent with prior expectations, suggesting that respondents understood the 
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DCE task and made choices in a manner consistent with the assumptions of random utility 
theory. The MNL model was presented in supplementary table 1 and presents consistent 
results. 
 
Supplementary table 1: Multinomial logit model 
   
   Adult Females   Adult Males  
Products: Vaginal ring -1.13 (0.07)*** - 
                  Implant -0.01 (0.06) -0.59 (0.06)*** 
                  Injectable 0.19 (0.06)*** -0.37 (0.06)*** 
                  Circumcision - -0.21 (0.04)*** 
                  Oral PrEP (base)     
Protection: HIV protection (100%) 3.22 (0.16)*** 3.13 (0.12)*** 
                   Pregnancy prevention 0.34 (0.05)*** 0.28 (0.04)*** 
                   STI protection 0.09 (0.05)* 0.19 (0.04)*** 
Ability to use in secret 0.12 (0.05)*** 0.09 (0.04)** 
Waiting time 0.04 (0.03) 0.09 (0.02)*** 
Opt-out 3.03 (0.14)*** 0.7 (0.14)*** 
Male condom 0.84 (0.11)*** -0.37 (0.2)* 
    
 
 
 
Among adult women, the intravaginal ring is the least preferred product modality. Oral 
PrEP, an injectable and an implant valued similarly. Among adult men, oral PrEP is 
preferred over any other product or method, with an implant indicated to be the least 
preferred option. Men prefer new products to the male condom, whereas women were 
more likely to choose condom use over new products. 
 
In both groups, HIV protection was the most influential determinant of choice suggesting 
that efficacy of products would be critical in driving demand. Respondents also showed 
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strong preferences for MPTs. Pregnancy and STI protection were significantly valued by 
both men and women, though pregnancy protection was valued three-times higher than 
STI protection among women and almost two times higher among men. Although not 
influential to the choices of women, a degree of waiting time was valued amongst men.  
 
Men were more likely to choose a new product than women, as shown by significant opt-
out parameters with different signs. Finally, whilst adult women value the use of male 
condoms, the opposite is true amongst adult males, and the significantly negative 
coefficient for male condom indicates that men who currently use condoms are likely to 
move to new products.  
       Table 3: Mixed multinomial logit model 
  Males Females 
  Mean SD Mean SD 
Products:   Oral PrEP (base)         
                  Implant -1.260*** 2.655*** -0.125 3.105*** 
  (0.189) (0.197) (0.205) (0.231) 
                  Injectable -1.084*** 2.320*** -0.223 3.326*** 
  (0.167) (0.178) (0.195) (0.252) 
                  Circumcision* -0.821*** 3.119***     
  (0.171) (0.216)     
                  Vaginal ring†     -3.616*** 3.772*** 
      (0.345) (0.331) 
Protection: HIV protection (100%) 0.0742*** -0.0669*** 0.0668*** -0.0541*** 
  (0.00510) (0.00462) (0.00489) (0.00370) 
                   Pregnancy prevention 0.578*** 0.873*** 0.710*** 1.091*** 
  (0.0820) (0.0967) (0.109) (0.124) 
                   STI protection 0.302*** -0.500*** 0.0792 -0.496*** 
  (0.0728) (0.129) (0.0914) (0.130) 
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Ability to use in secret 0.191*** 0.158 0.131 -0.310** 
  (0.0644) (0.168) (0.0843) (0.124) 
Waiting time 0.0997*** -0.00398 0.0498 -0.163* 
  (0.0386) (0.0700) (0.0518) (0.0834) 
Opt-out -2.361*** -3.076*** 3.037*** 9.543*** 
  (0.528) (0.499) (0.425) (0.630) 
Male condom 0.173 0.439 11.17*** 4.082*** 
  (0.534) (0.586) (0.862) (0.392) 
Number of choices 16,240 16,240 15,208 15,208 
* For men only † For females only. Coefficients shown with standard errors in parentheses.  
***, **, * ==> Significance at 1%, 5%, 10% level. 1,000 Halton draws.   
 
Uptake predictions 
Figure 2 shows uptake predictions from the MNL model for male and female groups, with 
data weighted to consider migration from condoms, using reported data of condom use at 
last sex; 12% among women, and 26% among men. These results are subject to the IIA 
assumption required in the MNL model, and do not give a guide to absolute uptake, but 
can provide a useful indication of uptake patterns. Among women, there were comparable 
levels of demand for oral PrEP, injectable, and implant products, however uptake of an 
intravaginal ring was predicted to be substantively lower. Condom use was not predicted 
to be substantially affected by the introduction of new products amongst women, although 
we predicted condom use to decrease among men by around one third. 
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Figure 2: Multinomial logit uptake predictions by sex 
 
 
Preference heterogeneity 
Preference heterogeneity was explored through latent class models shown in table 4, run 
separately and without sample weighting for male and female samples. Three latent 
classes were used for each model. Men in class 1 demonstrated very strong preferences 
for HIV protection and no preference for STI or pregnancy protection. Men in this class 
were likely to avoid choosing new products at all and particularly dislike the implant and 
injectable products. Relative to class 3, men in this group were more likely to be older and 
more likely to have ever used drugs.  
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The characteristics of men in classes 2 and 3 were statistically similar, and although men 
in these classes would preferred products offering multipurpose protection from HIV, STIs, 
and pregnancy, other preference differed. For example, men in class 3 found the injectable 
product, and circumcision attractive whilst men in class 2 did not. Men in class 3 also found 
the male condom an unappealing product and were likely to choose unprotected sex more 
than men in class 2. Finally, the preference for longer waiting times is only weakly 
statistically significant among one male group in this model, in contrast to the MMNL 
findings of a preference for waiting longer.  
 
Female preferences were variable, and were impacted by structural factors including 
exposure to intimate partner violence (IPV). There was heterogeneity in preferences for 
multipurpose prevention products. Whereas women in class 1 strongly valued a 
contraceptive and HIV protective product, women in classes 2 and 3 valued HIV and STI 
protection only. We identified a comparatively more vulnerable class of women who were 
more likely to have experienced IPV in the previous year and were less likely to make 
decisions around their health and finances (class 2 relative to class 3). Class 2 women had 
strong, positive preferences for the longer-lasting products of the implant, injectable, and 
vaginal ring compared to oral PrEP, and significantly valued secrecy of use. By contrast, 
women likely to be in class 1 strongly preferred the implant over all other products and 
found contraceptive protection attractive. Class 1 women were also more likely to be older 
and with prior IPV. Finally, the largest and least vulnerable class identified was class 3 in 
which 53% strongly preferred oral PrEP over any other product. 
Table 4: Latent class model 
  Males     Females     
  Class 1 Class 2 Class 3 Class 1 Class 2 Class 3 
Class membership 
probability 
36% 40% 25% 26% 21% 53% 
Products:   Oral PrEP (base)             
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                  Implant -1.42*** -0.77*** -0.1 3.51*** 1.91*** -0.76*** 
  (0.17) (0.11) (0.17) (0.54) (0.25) (0.1) 
                  Injectable -0.96*** -0.56*** 0.51*** 0.52 2.31*** -0.23*** 
  (0.27) (0.07) (0.18) (0.8) (0.23) (0.07) 
                  Circumcision* 0.06 -1.88*** 1.67***    
  (0.16) (0.12) (0.14)    
                  Vaginal ring†    0.12 1.06*** -2.27*** 
     (0.64) (0.24) (0.12) 
Protection: HIV protection 
(100%) 
9.3*** 1.87*** 1.15*** 7.18*** 4.5*** 4.79*** 
  (0.52) (0.52) (0.52) (2.0) (0.44) (0.27) 
                   Pregnancy 
prevention 
0.08 0.3*** 0.6*** 1.86*** 0.12 0.12 
  (0.13) (0.07) (0.12) (0.59) (0.13) (0.08) 
                   STI protection 0.06 0.19** 0.41*** 0.51 0.67*** -0.1*** 
  (0.2) (0.09) (0.12) (0.91) (0.16) (0.11) 
Ability to use in secret 0.17 0.24** 0.04 -0.29 0.29* 0.13* 
  (0.17) (0.1) (0.14) (0.69) (0.15) (0.09) 
Waiting time 0.03 0.12* 0.02 -1.04* -0.23** -0.04** 
  (0.11) (0.07) (0.09) (0.54) (0.09) (0.06) 
Opt-out 2.95*** -1.21*** 1.67*** 11.73*** 5.05*** 2.08*** 
  (0.85) (0.27) (0.35) (2.45) (0.51) (0.19) 
Male condom -0.42 -0.22 -0.87*** 1.22** -0.2 -0.13 
  (2.37) (0.34) (0.17) (0.53) (0.27) (0.35) 
              
Class membership 
predictors 
            
Circumcised -0.04 -0.51         
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Makes no household decisions -0.18 -0.04   0.32 -1.34***   
No household hunger -0.32 -0.22   -0.17 0.05   
Ever drink alcohol -0.21 -0.19   0.42 0.57   
Ever used drugs 1.65** 1.01   -0.14 -0.97   
Age 0.03* 0.02   0.04*** 0.0   
Experienced IPV in last year       1.41*** 1.59***   
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DISCUSSION 
Fishing communities in Uganda are an important population for HIV prevention given 
high rates of transmission. This is the first study, to our knowledge, that elicits the 
preferences of members of this sub-population to assess potential demand for a range of 
new ARV-based HIV prevention products for PrEP. We found that products were 
generally attractive and acceptable to potential users, but preferences for specific 
product modalities and attributes were heterogeneous. 
For example, the largest group identified in a latent class analysis found oral PrEP the 
most attractive product to women. However, more vulnerable women (i.e. younger 
women, women using alcohol, women who had experienced intimate partner violence 
(IPV) in the previous year and women who do not make household decisions) 
significantly valued other products such as implants and injectable PrEP over oral PrEP.  
The attractiveness of oral PrEP among males could lead to relatively high HIV protection 
and even higher protection if oral PrEP, condom use and male circumcision are 
considered. These results indicate that a one-size-fits-all approach to HIV prevention 
programming (for example, only introducing one product) will not maximize benefits, 
and may lead to misallocation of scarce resources, particularly in our fishing 
communities. 
 
Correlations between heterogeneity in the HIV risk in fishing communities and their 
preferences for new products need to be accounted for so that effective, attractive 
products get into the hands of those who will use them well. Evidence suggests that the 
HIV prevention field can learn from successes and failures in contraceptive programming 
(54), in particular the need to focus on creating an attractive product mix versus 
provision of single technology products. 
 
Strong evidence for a bidirectional relationship between IPV and HIV/AIDS has emerged 
from prospective cohort studies (55, 56). Fishing communities face several structural 
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barriers to HIV including IPV (31, 57). Our study further showed that IPV might inform 
decision making on preferences for HIV prevention methods. To be effective, HIV 
combination prevention interventions for fishing communities must be implemented 
using approaches that build individual agency, self-efficacy and skills that strengthen 
community cohesion to improve uptake of prevention products. Some projects already 
do this, such as (Safe Homes And Respect for Everyone) SHARE, a combined IPV and 
HIV prevention intervention which resulted in a significant decline in physical and sexual 
violence and HIV incidence, in a general population in rural Uganda (58). 
 
Previous studies have highlighted some of the barriers to PrEP use including HIV-related 
stigma, limited knowledge of PrEP, and inadequate access to PrEP (59-61). In addition, 
controversies over global inequalities in access to ART including PrEP persist. For 
instance coverage of ART for those eligible is still quite low, and expanding PrEP services 
may be similarly suboptimal (62). However, the results of this study suggest that, if 
supply-side barriers can be overcome, there may be substantial demand for new 
prevention options from the fishing communities as a high-risk group.  
 
Among women, condom use is not predicted to be substantially affected by the 
introduction of new products, suggesting that risk compensation (63)—where people 
adjust their behavior in response to the perceived level of risk may not occur. However, 
we predict a one-third reduction in condom use among men because men prefer new 
products to the male condom. Men’s potential to stop using condoms in preference to 
PrEP has implications for HIV and other sexually transmitted infections and 
contraception. More research is needed to understand the contexts in which risk 
compensation occurs to a greater or lesser extent, and to understand how this might 
affect product impact. 
 
Our results also highlight that MPTs could potentially fill significant unmet sexual and 
reproductive health needs in fishing communities with high HIV incidence of curable STI 
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(4)(64) and inadequate contraception provision. MPTs increase efficiencies in delivery 
and access to products. Furthermore, increased demand for MPTs may indirectly improve 
contraception and STI control coverage (65). MPTs have been predicted to be cost-
effective in high-risk female sex workers and young women in South Africa (66); more 
research is needed on the cost-effectiveness of MPTs in different contexts. 
  
Study strengths and limitations 
 
A major strength of our study was that the DCE approach allows us to explore fishing 
communities’ demand and preferences for both old, new and upcoming HIV prevention 
techniques.  The study was conducted prior to the roll-out of oral PrEP, and findings can 
be used to inform strategic implementation of oral PrEP and other new HIV prevention 
products that may be developed. We provided respondents with actual products instead 
of visual representations of the product, which aided individual evaluation of the 
products and attributes, making our results more valid than if all choices had been  
presented hypothetically. Nevertheless, the imperfect external validity of DCEs imply 
that results may differ from revealed preferences. Uptake predictions based on 
hypothetical data analysed with an MNL model may differ from those chosen in reality. 
We selected respondents using stratified random sampling from two urban and two rural 
communities. Thus, our findings may be generalizable to similar fishing communities 
elsewhere in Uganda and other parts of East Africa.  
 
The actual cost of the prevention methods might influence the real-world choice of 
prevention methods for both the provider and the end user. However, we did not explore 
real or probable product cost because we could not ascertain whether new HIV 
prevention products would be available free or at a subsidized cost by the government of 
Uganda. Currently, the available prevention products are highly subsidized by 
government and often offered free of charge in public health facilities although condoms 
are also sold in private facilities at less than 50 cents. 
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All information analyzed in this work was based on self-reported behavior, which may be 
subject to social desirability bias, especially so for this study population that receives 
frequent safer HIV prevention messaging, potentially leading to over-reporting of 
condom use and prevention product use. We used the multinomial logit model to predict 
uptake which requires the restrictive independence of irrelevant alternatives assumption 
to hold. Therefore our results should be used as a guide to the pattern of demand. We 
could not find a satisfactory explanation for why a degree of waiting time was valued 
amongst some men, though the latent class analysis suggests that this is not the case 
once heterogeneity has been considered. 
 
Recommendations and conclusion 
Oral PrEP is acceptable among fishing communities. Both men and women had a strong 
preference for oral PrEP although preferences for products and product attributes were 
heterogeneous. Future work should explore actual utility of MPTs among fisherfolk in 
Uganda as part of a combination HIV prevention package. 
 
References 
1. UNAIDS. Fact sheet: Global HIV statistics 2017 [Available from: 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. 
2. Seeley J, Nakiyingi-Miiro J, Kamali A, Mpendo J, Asiki G, Abaasa A, et al. High HIV 
incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake 
Victoria, Uganda. Sexually transmitted diseases. 2012;39(6):433-9. 
3. Kiwanuka N, Ssetaala A, Mpendo J, Wambuzi M, Nanvubya A, Sigirenda S, et al. 
High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials 
in fishing communities on Lake Victoria, Uganda. Journal of the International AIDS Society. 
2013;16(1). 
28 
 
4. Kiwanuka N, Ssetaala A, Nalutaaya A, Mpendo J, Wambuzi M, Nanvubya A, et al. 
High incidence of HIV-1 infection in a general population of fishing communities around 
Lake Victoria, Uganda. PLoS ONE. 2014;9(5):e94932. 
5. Ministry of Health. National HIV Prevention Strategy 2011 - 2015 [Available from: 
http://www.aidsuganda.org/images/documents/NPS.pdf. 
6. Kamali A, Price M, Lakhi S, Karita E, Inambao M, Sanders E, et al. Creating an 
African HIV Clinical Research and Prevention Trials Network: HIV Prevalence, Incidence 
and Transmission. PloS one. 2014;10(1):e0116100-e. 
7. Asiki G, Baisley K, Kamali A, Kaleebu P, Seeley J, Newton R. A prospective study 
of trends in consumption of cigarettes and alcohol among adults in a rural Ugandan 
population cohort, 1994–2011. Tropical medicine & international health. 2015;20(4):527-
36. 
8. Opio A, Muyonga M, Mulumba N. HIV Infection in Fishing Communities of Lake 
Victoria Basin of Uganda–A Cross-Sectional Sero-Behavioral Survey. PloS one. 
2013;8(8):e70770. 
9. Allison EH, Seeley J. Another group at high risk for HIV. Science. 
2004a;305,(1104.). 
10. Kissling E, Allison EH, Seeley JA, Russell S, Bachmann M, Musgrave SD, et al. 
Fisherfolk are among groups most at risk of HIV: cross-country analysis of prevalence and 
numbers infected. AIDS. 2005;19(17):1939-46. 
11. Kiwanuka N, Ssetaala A, Mpendo J, Wambuzi M, Nanvubya A, Sigirenda S, et al. 
High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials 
in fishing communities on Lake Victoria, Uganda. J Int AIDS Soc. 2013;16. 
12. Sileo K, Kintu M, Kiene S. History of sexual abuse, depression, and alcohol use as 
risk factors for HIV infection in high HIV prevalence fishing communities in rural Uganda. 
Ann Global Health. 2015;81. 
13. Tumwesigye NM, Atuyambe L, Wanyenze RK, Kibira SP, Li Q, Wabwire-Mangen F, 
et al. Alcohol consumption and risky sexual behaviour in the fishing communities: evidence 
from two fish landing sites on Lake Victoria in Uganda. BMC Public Health. 2012;12(1):1. 
29 
 
14. Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. 
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-
exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-
serodiscordant relationships: a randomized, clinical trial. PloS one. 2013;8(9):e74314. 
15. Kwena ZA, Camlin CS, Shisanya CA, Mwanzo I, Bukusi EA. Short-term mobility and 
the risk of HIV infection among married couples in the fishing communities along Lake 
Victoria, Kenya. PloS one. 2013;8(1):e54523. 
16. Nunan F. Mobility and fisherfolk livelihoods on Lake Victoria: Implications for 
vulnerability and risk. Geoforum. 2010;41(5):776-85. 
17. Nunan F, Luomba J, Lwenya C, Yongo E, Odongkara K, Ntambi B. Finding space for 
participation: fisherfolk mobility and co-management of Lake Victoria fisheries. 
Environmental management. 2012;50(2):204-16. 
18. Uganda HIV/AIDS knowledge management communications capacity. Most at risk 
populations-fishing communities and HIV in Uganda: Synthesis of information and 
evidence to inform the response. 2014. 
19. Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, et al. HIV 
pre-exposure prophylaxis in men who have sex with men and transgender women: a 
secondary analysis of a phase 3 randomised controlled efficacy trial. The Lancet Infectious 
Diseases. 2014;14(6):468-75. 
20. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. 
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New 
England Journal of Medicine. 2012;367(5):399-410. 
21. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. 
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. 
New England Journal of Medicine. 2012;367(5):423-34. 
22. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. 
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention 
of HIV infection in women. Science. 2010;329(5996):1168-74. 
30 
 
23. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure 
chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal 
of Medicine. 2010;363(27):2587-99. 
24. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit 
M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, 
Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled 
phase 3 trial. The Lancet. 2013;381(9883):2083-90. 
25. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. 
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who 
have sex with men. Science Translational Medicine. 2012;4(151):151ra25-ra25. 
26. McCormack S, editor Pragmatic Open-Label Randomised Trial of Preexposure 
Prophylaxis: The PROUD Study.  Conference on Retroviruses and Opportunistic Infections 
(CROI), Seattle, USA, abstract 22LB2015. 
27. Ministry of Health Uganda. Consolidated guidelines for prevention and treatment of 
HIV in Uganda 2016 [Available from: 
https://aidsfree.usaid.gov/sites/default/files/uganda_hiv_gl_2016.pdf. 
28. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, 
et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New 
England Journal of Medicine. 2016;375(22):2121-32. 
29. Nel A, van Niekerk N, Kapiga S, Bekker L-G, Gama C, Gill K, et al. Safety and 
efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of 
Medicine. 2016;375(22):2133-43. 
30. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-
based preexposure prophylaxis for HIV infection among African women. New England 
Journal of Medicine. 2015;372(6):509-18. 
31. HIV Prevention Trials Network. HPTN: A Phase 3 Double Blind Safety and Efficacy 
Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-
Exposure Prophylaxis in HIV-Uninfected Women 2018 [Available from: 
https://www.hptn.org/research/studies/hptn084. 
31 
 
32. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male 
circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. The Lancet. 
2007;369(9562):657-66. 
33. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male 
circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled 
trial. The lancet. 2007;369(9562):643-56. 
34. Centre for Disease Control. Pre-exposure Prophylaxis for the Prevention of HIV 
Infection in the United States 2014 [Available from: 
http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. 
35. World Health Organization. Consolidated guidelines on general HIV care and the 
use of antiretroviral drugs for treating and preventing HIV infection: recommendations for 
a public health approach.    
 2013 [Available from: 
(http://www.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. 
36. Baeten J, Celum C, editors. Antiretroviral pre-exposure prophylaxis for HIV-1 
prevention among heterosexual African men and women: the Partners PrEP Study. 6th 
IAS Conference on HIV Pathogenesis, treatment and Prevention; 2011. 
37. Mugwanya K, Donnell D, Celum C, Mugo N, Thomas K, Ngure K, et al. O11. 2 Sexual 
Behaviour of Heterosexual Men and Women Receiving Antiretroviral Pre-Exposure 
Prophylaxis For HIV Prevention: Post-Unblinding Analysis of the Partners PrEP Study. 
Sexually transmitted infections. 2013;89(Suppl 1):A46-A. 
38. Ndase P, Celum C, Campbell J, Bukusi E, Kiarie J, Katabira E, et al. Successful 
Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product 
After a Positive Interim Efficacy Result: The Partners PrEP Study Experience. JAIDS Journal 
of Acquired Immune Deficiency Syndromes. 2014;66(2):206-12. 
39. Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP 
trials: current status and a reconceptualization. Current Opinion in HIV and AIDS. 
2012;7(6):534. 
32 
 
40. Francis JM, Grosskurth H, Changalucha J, Kapiga SH, Weiss HA. Systematic review 
and meta‐analysis: prevalence of alcohol use among young people in eastern Africa. 
Tropical Medicine & International Health. 2014;19(4):476-88. 
41. AVAC Global advocacy for HIV prevention. Ongoing and Planned PrEP Trials and 
Demonstration Projects 2013 [Available from: http://www.prepwatch.org/wp-
content/uploads/2014/01/PrEP-Trials-and-Demo-Projects-December-2013.pdf. 
42. Seeley J, Tumwekwase G, Grosskurth H. Fishing for a living but catching HIV: AIDS 
and changing patterns of the organization of work in fisheries in Uganda. Anthropology of 
Work Review. 2009;30(2):66-76. 
43. Uganda Ministry of Agricultue, Animal Industry and Fisheries.(n.d). Departments: 
Fisheries Resources.  [Available from: http://www.agriculture.go.ug/index-page-
departments-id-87.htm. 
44. Boffito M, Jackson A, Owen A, Becker S. New approaches to antiretroviral drug 
delivery: challenges and opportunities associated with the use of long-acting injectable 
agents. Drugs. 2014;74(1):7-13. 
45. Kuteesa MO, Weiss HA, Abaas A, Nash S, Nsubuga RN, Newton R, et al. Feasibility 
of conducting HIV combination prevention interventions in fishing communities in Uganda: 
a cluster randomised trial. . In press2018. 
46. ChoiceMetrics. Ngene version 1.1.2. Sydney, Australia2012. 
47. Hensher D, Rose J, Greene W. Applied Choice Analysis: Second Edition. Cambridge: 
Cambridge University Press; 2015. 
48. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health 
economics: a review of the literature. Health Econ. 2012;21(2):145-72. 
49. Hess S, Bierlaire M, Polak JW. Estimation of value of travel-time savings using 
mixed logit models. Transportation Research Part A: Policy and Practice. 2005;39(2–
3):221-36. 
50. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly K R, Koechlin FM, et al. 
Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: 
A systematic review and meta-analysis. Aids. 2016. 
33 
 
51. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, 
et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New 
England Journal of Medicine. 2016. 
52. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual 
transmission of HIV. Family planning perspectives. 1999;31(6):272-9. 
53. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male 
circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 
2007;369(9562):657-66. 
54. Delany-Moretlwe S, Mullick S, Eakle R, Rees H. Planning for HIV preexposure 
prophylaxis introduction: lessons learned from contraception. Current Opinion in HIV and 
AIDS. 2016;11(1):87-93. 
55. Kouyoumdjian FG, Findlay N, Schwandt M, Calzavara LM. A systematic review of 
the relationships between intimate partner violence and HIV/AIDS. PLoS One. 
2013;8(11):e81044. 
56. Wagman JA, Gray RH, Campbell JC, Thoma M, Ndyanabo A, Ssekasanvu J, et al. 
Effectiveness of an integrated intimate partner violence and HIV prevention intervention 
in Rakai, Uganda: analysis of an intervention in an existing cluster randomised cohort. The 
Lancet Global Health. 2015;3(1):e23-e33. 
57. Sileo KM, Kintu M, Kiene SM. The intersection of intimate partner violence and HIV 
risk among women engaging in transactional sex in Ugandan fishing villages. AIDS care. 
2018;30(4):444-52. 
58. Wagman JA, King EJ, Namatovu F, Kiwanuka D, Kairania R, Semanda JB, et al. 
Combined intimate partner violence and HIV/AIDS prevention in rural Uganda: design of 
the SHARE intervention strategy. Health care for women international. 2016;37(3):364-
87. 
59. Idoko J, Ukpong MO, Dadem NY, Kolawole GO, Anenih J, Alhassan E. Why Should 
I Take Drugs for your Infection: Outcomes of Formative Research on Use of PrEP in Nigeria. 
AIDS research and human retroviruses. 2014;30(S1):A80-A1. 
34 
 
60. van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET, 
et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-
C qualitative study in Johannesburg, South Africa. Journal of the International AIDS 
Society. 2014;17(3Suppl 2). 
61. Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report. UNAIDS, 
Geneva, Switzerland 2014 [Available from: 
http://www.unaids.org/en/resources/documents/2014/20140716_UNAIDSgap_report. 
62. Belluz J. The Truvada wars. British Medical Journal. 2014;348:g3811. 
63. Graham J. Target Risk: Dealing with the Danger of Death, Disease and Damage in 
Everyday Decisions. Injury Prevention. 1998;4(2):162-3. 
64. Mbonye M, Nalukenge W, Nakamanya S, Nalusiba B, King R, Vandepitte J, et al. 
Gender inequity in the lives of women involved in sex work in Kampala, Uganda. Journal 
of the International AIDS Society. 2012;15 (no pagination)(633). 
65. Fernández-Romero JA, Deal C, Herold BC, Schiller J, Patton D, Zydowsky T, et al. 
Multipurpose prevention technologies: the future of HIV and STI protection. Trends in 
microbiology. 2015;23(7):429-36. 
66. Quaife M, Terris-Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne-Brook M, 
Mvundura M, et al. The cost-effectiveness of multi-purpose HIV and pregnancy prevention 
technologies in South Africa. J Int AIDS Soc. 2018;21(3). 
 
